On November 20, Business Day reported that state-backed vaccine developer Biovac is in discussion with several pharmaceutical companies developing Covid-19 vaccines to potentially manufacture shots in SA. The public-private partnership was established to revive SA’s human vaccine manufacturing capabilities, with the state owning 47.5% and the majority stake held by a private consortium led by Immunotek.

Biovac has the capacity to manufacture between 20-m and 30-m Covid-19 vaccines a year, depending on the technology involved. This is a fraction of the 300-m annual doses of Johnson & Johnson’s Covid-19 vaccine that Aspen plans to manufacture at its facility in Port Elizabeth.


Other news